Prioritizing investments in innovations to protect women from the leading causes of maternal death

BMC Pregnancy and Childbirth

Paul D LaBarre¹  Michael J Free¹  Patricia S Coffey¹  Alice M Levisay¹  Claudia M Harner-Jay¹  Tara M Herrick¹ 

[1] PATH, PO Box 900922, Seattle, WA 98109, USA

关键词: Proteinuria test;    Blood pressure measurement;    Uterine balloon tamponade;    Magnesium sulfate;    Oxytocin;    Technology assessment;    Eclampsia;    Preeclampsia;    Postpartum hemorrhage;    Maternal health;   

Others  :  1131801
DOI  :  10.1186/1471-2393-14-10

 received in 2013-04-26, accepted in 2014-01-03,  发布年份 2014

【 摘 要 】

PATH, an international nonprofit organization, assessed nearly 40 technologies for their potential to reduce maternal mortality from postpartum hemorrhage and preeclampsia and eclampsia in low-resource settings. The evaluation used a new Excel-based prioritization tool covering 22 criteria developed by PATH, the Maternal and Neonatal Directed Assessment of Technology (MANDATE) model, and consultations with experts. It identified five innovations with especially high potential: technologies to improve use of oxytocin, a uterine balloon tamponade, simplified dosing of magnesium sulfate, an improved proteinuria test, and better blood pressure measurement devices. Investments are needed to realize the potential of these technologies to reduce mortality.

【 授权许可】

   
2014 Herrick et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Howett P, Darzi A, Yang G-Z, et al.: Technologies for global health. Lancet 2012, 380:507-535.
• [2]Sinha SR, Barry M: Health technologies and innovation in the global health arena. N Engl J Med 2011, 365(9):779-782.
• [3]World Health Organization (WHO): Trends in Maternal Mortality: 1990 to 2010. Geneva: WHO; 2012.
• [4]Nations U: Millennium Development Goals Report 2012. New York: United Nations; 2012.
• [5]Shelton JD: Twenty criteria to make the best of scarce health resources in developing countries. BMJ 2011, 343:d7023.
• [6]United Nations Commission on Life-Saving Commodities for Women and Children: Commissioners’ Report September 2012. New York: United Nations; 2012.
• [7]MDG5 Meshwork for Improving Maternal Health: Public private partnership for the development of heat-stable oxytocin. 2010. Available at: http://www.mdg5-meshwork.org/content/public-private-partnership-development-heat-stable-oxytocin webcite. Accessed 4 December 2012
• [8]World Health Organization (WHO): Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta. Geneva: WHO; 2012. Available at: http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf webcite. Accessed 7 December 2012
• [9]Doumouchtsis SK, Papageorghiou AT, Vernier C, Arulkumaran S: Management of postpartum hemorrhage by uterine balloon tamponade: prospective evaluation of effectiveness. Acta Obstet Gynecol Scand 2008, 87:849-855.
• [10]Tindell K, Garfinkel R, Abu-Haydar E, et al.: Uterine balloon tamponade for the treatment of postpartum haemorrhage in resource-poor settings: a systematic review. BJOG 2012. doi:10.1111/j.1471-0528.2012.03454.x. [Epub ahead of print]
• [11]World Health Organization (WHO): WHO Recommendations for the Prevention and Treatment of Preeclampsia and Eclampsia. Geneva: WHO; 2011.
• [12]Dhakal G, Subedi M, Paudel K: Magnesium sulphate in management of severe pre-eclampsia and eclampsia. J Nepal Health Res Counc 2012, 10(21):113-117.
• [13]Osungbade KO, Ige OK: Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy 2011., 481095doi: 10.1155/2011/481095
• [14]Villar J, Say L, Shennan A, et al.: Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of preeclampsia and eclampsia. Int J Gynaecol Obstet 2004, 85:S28-S41.